Description: Immunovaccine Inc. is a clinical-stage biopharmaceutical company. The Company develops products based on its vaccine enhancement platform with a primary focus on T lymphocytes (T cell) activating therapies for cancer. The Company's DepoVax adjuvanting/delivery platform produces immune response that has a specific and sustained immune effect and enables the Company to pursue vaccine candidates in cancer, infectious diseases and other vaccine applications. The DepoVax platform is used in multiple vaccine candidates, including over two-cancer vaccine candidates that have completed Phase I clinical trials. Its lead cancer vaccine, DPX- Survivac, is tested in a company-sponsored Phase II trial in lymphoma and a Phase Ib trial in ovarian cancer. Its infectious disease vaccine against respiratory syncytial virus (RSV) is in a Phase I clinical trial in Halifax, Nova Scotia.
Home Page: www.imv-inc.com
IMV Technical Analysis
130 Eileen Stubbs Avenue
Dartmouth,
NS
B3B 2C4
Canada
Phone:
902 492 1819
Officers
| Name | Title |
|---|---|
| Mr. Andrew Hall M.Sc. | CEO & Director |
| Dr. Jeremy R. Graff | Chief Scientific Officer |
| Ms. Brittany Davison C.A., CPA | Corp. Sec. & Chief Accounting Officer |
| Delphine Davan | Sr. Director of Communications & Investor Relations |
| Ms. Linda Barabe M.B.A. | Sr. VP of HR & Internal Communications |
| Dr. Marianne Stanford | VP of R&D |
| Mr. Stephan Fiset | VP of Clinical Research |
| Dr. Heather Hirsch | VP of Translational Research |
Exchange: TO
Country: CA : Canada
Currency: Canadian Dollar (C$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 8.951 |
| Price-to-Sales TTM: | 1779.9082 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 97 |